Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients

AIDS

Volumn 22, Issue 10, 2008, Pages 1234-1236

  Bani Sadr, Firouzé ^a,i   Miailhes, Patrick ^b   Rosenthal, Eric ^c   Yazdanpanah, Yazdan ^d   Boyer, Laurence ^e   Zucman, David ^f   Cacoub, Patrice ^g   Perronne, Christian ^h   Pol, Stanislas ^a   Carrat, Fabrice ^a  

^a INSERM   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f FOCH HOSPITAL   (France)

^g Université de Versailles ^*  (France)

^h RAYMOND POINCARÉ HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALKALINE PHOSPHATASE; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CORRELATION ANALYSIS; DRUG METABOLISM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; VIRUS LOAD; ENZYMOLOGY; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METABOLISM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPIDEMIOLOGIC METHODS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 50949107051     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fbd203     Document Type: Letter

References (9)

1. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40:174-181.
2. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17:721-725.
3. Tutor-Crespo M, Hermida J, Tutor C. Isoforms of serum gammaglutamyltransferase in epileptic patients treated with enzymeinducing anticonvulsant drugs. J Pharm Pharm Sci 2004; 7:353-358.
4. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34:504-510.
5. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
6. Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20:716-722.
7. Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, et al. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 2005; 56:790-792.
8. Barreiro P, Rodriguez-Novoa S, Labarga P, Ruiz A, Jimenez-Nacher I, Martin-Carbonero L, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007; 195:973-979.
9. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.